Zymeworks Cost Of Revenue vs Net Income Analysis

ZYME Stock

USD 13.10 0.04 0.31%

Zymeworks Common financial indicator trend analysis is more than just analyzing Zymeworks Common Stock current accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Zymeworks Common Stock is a good investment. Please check the relationship between Zymeworks Common Cost Of Revenue and its Net Income accounts. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zymeworks Common Stock. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

Cost Of Revenue vs Net Income

Cost Of Revenue vs Net Income Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Zymeworks Common Stock Cost Of Revenue account and Net Income. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Zymeworks Common's Cost Of Revenue and Net Income is -0.41. Overlapping area represents the amount of variation of Cost Of Revenue that can explain the historical movement of Net Income in the same time period over historical financial statements of Zymeworks Common Stock, assuming nothing else is changed. The correlation between historical values of Zymeworks Common's Cost Of Revenue and Net Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cost Of Revenue of Zymeworks Common Stock are associated (or correlated) with its Net Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Income has no effect on the direction of Cost Of Revenue i.e., Zymeworks Common's Cost Of Revenue and Net Income go up and down completely randomly.

Correlation Coefficient

-0.41

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Cost Of Revenue

Cost of Revenue is found on Zymeworks Common Stock income statement and represents the costs associated with goods and services Zymeworks Common provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Net Income

Net income is one of the most important fundamental items in finance. It plays a large role in Zymeworks Common Stock financial statement analysis. It represents the amount of money remaining after all of Zymeworks Common Stock operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.

Most indicators from Zymeworks Common's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Zymeworks Common Stock current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zymeworks Common Stock. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

At present, Zymeworks Common's Sales General And Administrative To Revenue is projected to slightly decrease based on the last few years of reporting. The current year's Enterprise Value is expected to grow to about 891.1 M, whereas Tax Provision is projected to grow to (539.6 K).

	2021	2022	2023	2024 (projected)
Interest Expense	12.9M	3.6M	4.1M	5.8M
Depreciation And Amortization	9.6M	12.0M	17.3M	18.2M

Interest Expense Depreciation And Amortization

Zymeworks Common fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Short Long Term Debt	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Property Plant Equipment
Total Assets		0.9	0.93	0.65	0.92	0.89	0.86	-0.88	-0.89	0.97	0.89	0.81	0.79	0.99	0.86	0.97	-0.31	0.8	0.27	0.92	-0.17	0.99	0.52	0.83	0.98	0.79
Other Current Liab	0.9		0.96	0.55	0.89	0.74	0.81	-0.87	-0.84	0.9	0.88	0.67	0.75	0.92	0.75	0.86	-0.16	0.91	0.28	0.9	-0.21	0.92	0.3	0.72	0.87	0.59
Total Current Liabilities	0.93	0.96		0.47	0.89	0.77	0.82	-0.89	-0.82	0.95	0.9	0.69	0.77	0.95	0.76	0.87	-0.18	0.82	0.13	0.94	-0.17	0.95	0.33	0.79	0.88	0.66
Total Stockholder Equity	0.65	0.55	0.47		0.4	0.77	0.65	-0.67	-0.75	0.62	0.68	0.74	0.62	0.6	0.81	0.71	-0.56	0.6	0.87	0.49	-0.14	0.62	0.67	0.4	0.7	0.75
Other Liab	0.92	0.89	0.89	0.4		0.78	0.8	-0.71	-0.84	0.88	0.73	0.75	0.71	0.91	0.65	0.88	-0.26	0.8	0.03	0.91	-0.16	0.91	0.43	0.84	0.9	0.67
Net Tangible Assets	0.89	0.74	0.77	0.77	0.78		0.74	-0.74	-0.9	0.84	0.75	0.93	0.66	0.87	0.76	0.89	-0.7	0.65	0.37	0.75	-0.26	0.87	0.82	0.71	0.88	0.94
Property Plant And Equipment Net	0.86	0.81	0.82	0.65	0.8	0.74		-0.8	-0.91	0.87	0.84	0.78	0.97	0.81	0.87	0.92	-0.27	0.88	0.43	0.87	-0.11	0.83	0.46	0.74	0.92	0.78
Net Debt	-0.88	-0.87	-0.89	-0.67	-0.71	-0.74	-0.8		0.75	-0.9	-1.0	-0.6	-0.81	-0.9	-0.92	-0.84	0.14	-0.73	-0.4	-0.8	0.24	-0.91	-0.3	-0.61	-0.83	-0.66
Retained Earnings	-0.89	-0.84	-0.82	-0.75	-0.84	-0.9	-0.91	0.75		-0.87	-0.78	-0.94	-0.83	-0.84	-0.79	-0.93	0.57	-0.89	-0.47	-0.86	0.16	-0.85	-0.7	-0.75	-0.93	-0.88
Accounts Payable	0.97	0.9	0.95	0.62	0.88	0.84	0.87	-0.9	-0.87		0.91	0.79	0.83	0.96	0.87	0.95	-0.28	0.8	0.28	0.95	-0.07	0.97	0.48	0.8	0.94	0.78
Cash	0.89	0.88	0.9	0.68	0.73	0.75	0.84	-1.0	-0.78	0.91		0.62	0.85	0.91	0.94	0.87	-0.14	0.76	0.42	0.82	-0.22	0.92	0.31	0.62	0.85	0.67
Non Current Assets Total	0.81	0.67	0.69	0.74	0.75	0.93	0.78	-0.6	-0.94	0.79	0.62		0.7	0.75	0.69	0.85	-0.75	0.7	0.4	0.77	-0.02	0.76	0.86	0.78	0.85	0.95
Non Currrent Assets Other	0.79	0.75	0.77	0.62	0.71	0.66	0.97	-0.81	-0.83	0.83	0.85	0.7		0.75	0.88	0.84	-0.19	0.81	0.43	0.84	-0.01	0.77	0.35	0.7	0.83	0.73
Cash And Short Term Investments	0.99	0.92	0.95	0.6	0.91	0.87	0.81	-0.9	-0.84	0.96	0.91	0.75	0.75		0.83	0.94	-0.26	0.76	0.21	0.9	-0.22	1.0	0.46	0.8	0.94	0.74
Net Receivables	0.86	0.75	0.76	0.81	0.65	0.76	0.87	-0.92	-0.79	0.87	0.94	0.69	0.88	0.83		0.89	-0.23	0.71	0.59	0.76	-0.11	0.85	0.45	0.59	0.87	0.76
Common Stock Shares Outstanding	0.97	0.86	0.87	0.71	0.88	0.89	0.92	-0.84	-0.93	0.95	0.87	0.85	0.84	0.94	0.89		-0.37	0.83	0.39	0.88	-0.21	0.95	0.6	0.75	0.99	0.84
Inventory	-0.31	-0.16	-0.18	-0.56	-0.26	-0.7	-0.27	0.14	0.57	-0.28	-0.14	-0.75	-0.19	-0.26	-0.23	-0.37		-0.19	-0.32	-0.24	0.09	-0.27	-0.94	-0.28	-0.35	-0.76
Other Current Assets	0.8	0.91	0.82	0.6	0.8	0.65	0.88	-0.73	-0.89	0.8	0.76	0.7	0.81	0.76	0.71	0.83	-0.19		0.46	0.84	-0.15	0.78	0.32	0.66	0.85	0.58
Other Stockholder Equity	0.27	0.28	0.13	0.87	0.03	0.37	0.43	-0.4	-0.47	0.28	0.42	0.4	0.43	0.21	0.59	0.39	-0.32	0.46		0.16	-0.08	0.24	0.38	0.02	0.38	0.4
Total Liab	0.92	0.9	0.94	0.49	0.91	0.75	0.87	-0.8	-0.86	0.95	0.82	0.77	0.84	0.9	0.76	0.88	-0.24	0.84	0.16		0.11	0.9	0.39	0.88	0.89	0.71
Short Long Term Debt	-0.17	-0.21	-0.17	-0.14	-0.16	-0.26	-0.11	0.24	0.16	-0.07	-0.22	-0.02	-0.01	-0.22	-0.11	-0.21	0.09	-0.15	-0.08	0.11		-0.22	-0.12	0.19	-0.2	-0.11
Total Current Assets	0.99	0.92	0.95	0.62	0.91	0.87	0.83	-0.91	-0.85	0.97	0.92	0.76	0.77	1.0	0.85	0.95	-0.27	0.78	0.24	0.9	-0.22		0.47	0.8	0.95	0.75
Short Term Debt	0.52	0.3	0.33	0.67	0.43	0.82	0.46	-0.3	-0.7	0.48	0.31	0.86	0.35	0.46	0.45	0.6	-0.94	0.32	0.38	0.39	-0.12	0.47		0.41	0.58	0.88
Intangible Assets	0.83	0.72	0.79	0.4	0.84	0.71	0.74	-0.61	-0.75	0.8	0.62	0.78	0.7	0.8	0.59	0.75	-0.28	0.66	0.02	0.88	0.19	0.8	0.41		0.8	0.67
Common Stock	0.98	0.87	0.88	0.7	0.9	0.88	0.92	-0.83	-0.93	0.94	0.85	0.85	0.83	0.94	0.87	0.99	-0.35	0.85	0.38	0.89	-0.2	0.95	0.58	0.8		0.82
Property Plant Equipment	0.79	0.59	0.66	0.75	0.67	0.94	0.78	-0.66	-0.88	0.78	0.67	0.95	0.73	0.74	0.76	0.84	-0.76	0.58	0.4	0.71	-0.11	0.75	0.88	0.67	0.82

Click cells to compare fundamentals

Zymeworks Common Account Relationship Matchups

Zymeworks Common fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	368.2M	538.4M	389.1M	648.7M	580.9M	337.6M
Other Current Liab	45.6M	76.7M	65.4M	61.7M	39.8M	36.8M
Total Current Liabilities	82.6M	85.7M	71.9M	95.6M	55.8M	51.5M
Total Stockholder Equity	(290.7M)	409.9M	249.1M	493.0M	464.8M	488.0M
Other Liab	34.3M	37.0M	37.3M	35.4M	40.7M	22.5M
Net Tangible Assets	227.6M	375.0M	215.6M	472.2M	543.0M	570.2M
Property Plant And Equipment Net	16.5M	17.6M	49.8M	47.7M	37.5M	21.0M
Net Debt	(121.5M)	(233.4M)	(169.5M)	(372.8M)	(130.8M)	(137.4M)
Retained Earnings	(290.7M)	(471.3M)	(683.1M)	(558.8M)	(677.4M)	(643.6M)
Accounts Payable	5.3M	6.2M	5.2M	7.9M	6.2M	4.6M
Cash	128.5M	242.0M	201.9M	400.9M	157.6M	141.2M
Non Current Assets Total	56.4M	83.3M	100.9M	104.0M	168.0M	176.4M
Non Currrent Assets Other	3.0M	3.1M	13.7M	15.7M	7.3M	5.3M
Cash And Short Term Investments	298.9M	426.4M	252.6M	492.2M	374.3M	245.8M
Net Receivables	2.2M	15.3M	15.6M	33.4M	19.5M	10.9M
Common Stock Shares Outstanding	38.0M	50.4M	52.1M	65.2M	68.9M	42.3M
Liabilities And Stockholders Equity	(168.2M)	538.4M	389.1M	648.7M	580.9M	609.9M
Other Current Assets	10.7M	26.9M	40.0M	19.1M	19.1M	13.6M
Other Stockholder Equity	(443.6M)	163.6M	197.7M	151.6M	142.3M	149.4M
Total Liab	122.5M	128.5M	140.0M	155.8M	116.1M	92.7M
Total Current Assets	311.8M	455.1M	288.2M	544.7M	412.9M	266.6M
Short Term Debt	1.3M	2.7M	1.3M	6.6M	30.1M	31.6M
Intangible Assets	23.7M	22.9M	21.5M	26.4M	25.3M	19.8M
Common Stock	450.2M	724.2M	741.1M	906.8M	1.0B	510.8M
Property Plant Equipment	16.5M	12.2M	22.8M	47.7M	54.8M	57.5M
Short Long Term Debt Total	6.9M	8.6M	32.3M	28.1M	26.7M	28.1M
Current Deferred Revenue	30.3M	37.4M	57.6M	2.4M	3.7M	3.5M
Other Assets	21.8M	65.8M	34.4M	34.7M	39.9M	30.9M
Common Stock Total Equity	320.1M	450.2M	724.2M	741.1M	852.3M	894.9M
Short Term Investments	170.5M	184.3M	50.7M	91.3M	216.8M	116.2M
Non Current Liabilities Total	40.0M	42.8M	68.2M	60.1M	60.3M	45.8M
Capital Surpluse	12.3M	92.8M	163.6M	197.7M	227.4M	238.7M
Deferred Long Term Liab	18.3M	34.1M	34.5M	17.6M	20.3M	22.5M
Capital Lease Obligations	6.9M	8.6M	41.2M	28.1M	26.7M	15.4M
Non Current Liabilities Other	978K	8.7M	33.7M	3.0M	1.6M	1.5M
Net Invested Capital	245.7M	409.9M	317.6M	493.0M	464.8M	350.1M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

When determining whether Zymeworks Common Stock is a strong investment it is important to analyze Zymeworks Common's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Zymeworks Common's future performance. For an informed investment choice regarding Zymeworks Stock, refer to the following important reports:

How To Invest In Zymeworks

Details

Is Zymeworks Stock a good investment?

Details

What is Zymeworks Common's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zymeworks Common Stock. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zymeworks Common. If investors know Zymeworks will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zymeworks Common listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.49)

Revenue Per Share

0.831

Quarterly Revenue Growth

(0.03)

Return On Assets

(0.15)

Return On Equity

(0.29)

The market value of Zymeworks Common Stock is measured differently than its book value, which is the value of Zymeworks that is recorded on the company's balance sheet. Investors also form their own opinion of Zymeworks Common's value that differs from its market value or its book value, called intrinsic value, which is Zymeworks Common's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zymeworks Common's market value can be influenced by many factors that don't directly affect Zymeworks Common's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Zymeworks Common's value and its price as these two are different measures arrived at by different means. Investors typically determine if Zymeworks Common is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zymeworks Common's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Zymeworks Cost Of Revenue vs Net Income Analysis

Cost Of Revenue vs Net Income

Cost Of Revenue vs Net Income Correlation Analysis

Correlation Coefficient

Cost Of Revenue

Net Income

Zymeworks Common fundamental ratios Correlations

Zymeworks Common Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Zymeworks Common fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Cash And Short Term Investments
Cash And Short Term Investments	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Total Assets
Common Stock	+ 0.99	Common Stock Shares Outstanding
Common Stock	+ 0.98	Total Assets
Accounts Payable	+ 0.97	Total Assets

Cash	- 1.0	Net Debt
Short Term Debt	- 0.94	Inventory
Non Current Assets Total	- 0.94	Retained Earnings
Common Stock	- 0.93	Retained Earnings
Common Stock Shares Outstanding	- 0.93	Retained Earnings
Net Receivables	- 0.92	Net Debt